New drug firsekibart aims to tame lupus flares in Hard-to-Treat patients
NCT ID NCT07381465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests Firsekibart, a biologic that blocks IL-1, in 15 adults with mild to moderate lupus who still have symptoms despite standard therapy. Participants receive three shots over 8 weeks, then stop the drug to see if symptoms return. The goal is to see if this approach can reduce disease activity safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Firsekibart (an IL-1 inhibitor biologic drug given as a shot)
What this could lead to
If it works, this could offer a new treatment option for lupus patients with fever and inflammation who don't respond to standard therapies.
What could go wrong
This is a very small pilot study with only 15 people, no placebo group, and early results may not apply to all lupus patients. The drug is also stopped after 12 weeks to see if symptoms return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.